PTC THERAPEUTICS INC (PTCT:NASDAQ)
$68.69 -2.16 (-3.0487%)
Analysed PTC THERAPEUTICS INC (PTCT:NASDAQ) News Sources
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And DMD Uncertainty
05-04-2026
yahoo.com
Netflix initiated, Instacart upgraded: Wall Street's top analyst calls
30-03-2026
yahoo.com
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
25-03-2026
yahoo.com
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
21-03-2026
fool.com
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
21-03-2026
fool.com
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
20-03-2026
fool.com
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations
20-03-2026
yahoo.com
KROS: Is the Discount Book Value a Value Trap?
17-03-2026
yahoo.com
KROS Stock: What to Know About Rinvatercept in DMD
17-03-2026
yahoo.com
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
17-03-2026
yahoo.com
What is the current price of PTC THERAPEUTICS INC (PTCT:NASDAQ)?
The current price of PTC THERAPEUTICS INC (PTCT:NASDAQ) is $68.69.
PTC THERAPEUTICS INC (PTCT:NASDAQ) absolute price change since previous trading day?
The absolute price change of PTC THERAPEUTICS INC (PTCT:NASDAQ) since the previous trading day is $-2.16.
PTC THERAPEUTICS INC (PTCT:NASDAQ) percentage price change since previous trading day?
The percentage price change of PTC THERAPEUTICS INC (PTCT:NASDAQ) since the previous trading day is -3.0487%.
What is the most recent average sentiment score for PTC THERAPEUTICS INC (PTCT:NASDAQ)?
The most recent average sentiment score for PTC THERAPEUTICS INC (PTCT:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for PTC THERAPEUTICS INC (PTCT:NASDAQ)?
The most recent sentiment for PTC THERAPEUTICS INC (PTCT:NASDAQ) is .
SEC-8K** Filing Available For PTC THERAPEUTICS INC (PTCT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.